Skip header and navigation

1 records – page 1 of 1.

[Future supply of tuberculin in Germany]

https://arctichealth.org/en/permalink/ahliterature69292
Source
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2005 Apr;48(4):477-82
Publication Type
Article
Date
Apr-2005
Author
D. Sagebiel
B. Hauer
W. Haas
K. Magdorf
M. Priwitzer
R. Loddenkemper
Author Affiliation
DZK, Zum Heckeshorn 33, 14109 Berlin. lodd.Heck@zedat.fu-berlin.de
Source
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2005 Apr;48(4):477-82
Date
Apr-2005
Language
German
Publication Type
Article
Keywords
Commerce
Contact Tracing - statistics & numerical data
Drug Industry - legislation & jurisprudence
Drug Utilization - statistics & numerical data
English Abstract
Forecasting
Germany
Health Services Needs and Demand - statistics & numerical data - trends
Humans
Reference Standards
Therapeutic Equivalency
Tuberculin - diagnostic use
Tuberculin Test - standards - statistics & numerical data
Tuberculosis - diagnosis - prevention & control
Abstract
The manufacturers of the only tuberculin available up to now in Germany for intradermal TB tests according to Mantoux, Chiron Vaccines Behring, in 2004 unexpectedly stopped the production of the tuberculin Behring GT (GT="gereinigtes Tuberkulin"-purified protein derivative tuberculin). Only residual stocks were sold during the preceding months. The stocks of GT 10 were already depleted at the beginning of 2005, while there are small supplies left of GT 100 and GT 1000. As a temporary solution, Chiron Vaccines Behring is offering to import the Italian tuberculin Biocine PPD 5 IE lyophil produced by Chiron S.r.l. in Siena. As this is not licensed for sale in Germany, it is necessary to obtain an exceptional prescription (Einzelverordnung) according to section sign 73 (3) of the Federal Law Relating to the Manufacture and Distribution of Medicine (Arzneimittelgesetz, AMG). In the long term, Chiron Vaccines Behring plan to secure the supply of tuberculin in Germany by importing, starting in the summer of 2006, the tuberculin produced by Chiron Vaccines Evans in the UK (PPD Evans). However, these plans involve changing over to a different type of tuberculin twice within a very short period of time. Another problem is the unresolved issue of bioequivalence. Besides the above-mentioned tuberculins produced by Chiron Vaccines, a further possibility would be the import of the tuberculin PPD RT23 SSI of the Statens Serums Institute (Copenhagen/Denmark), which is recommended by the World Health Organization (WHO) as the standard tuberculin and which has already been introduced in several European countries, or of other tuberculins such as Tubersol (PPD CT68), which is used in the US. Together with the Robert Koch Institute (RKI) and the Paul Ehrlich Institute (PEI), the German Central Committee against Tuberculosis (DZK) is striving to find a solution, in view of the urgent need for an uninterrupted supply of tuberculin in Germany for diagnostic purposes and contact tracing. A uniform tuberculin should be used in all German regions as a basis to secure a standardized testing procedure and national comparability of test results. The estimated annual requirement for Germany is two million tuberculin test doses. The Statens Serum Institute is currently evaluating the possibility of licensing PPD RT23 SSI in Germany. Chiron Vaccines Behring communicated that it is not aiming to have the Biocine tuberculin licensed for Germany but intends to apply for a license for the tuberculin PPD Evans. Sanofi Pasteur MSD at this point does not intend to have a tuberculin like Tubersol (PPD CT68) licensed for Germany. Until a licensed tuberculin is again available in Germany, it would be very useful if, especially in settings where stocks of tuberculin are essential (e.g. public health services or hospital dispensaries), an exceptional import license could be obtained.
PubMed ID
15830261 View in PubMed
Less detail